CAD and Plasmodium falciparum malaria: Over the last ten years, an intensive medicinal chemistry effort has concentrated on the design of small-molecule inhibitors of CPs as novel antiparasitic agents, including against falciparum malaria [14], Chagas' disease (T. cruzi [16]) and African sleeping sickness (T. brucei [17]).